These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8673948)

  • 21. [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
    Lardoux H; Maison Blanche P; Marchand X; Canler A; Rouesnel P; Bleinc D; Péraudeau P; Scheck F
    Ann Cardiol Angeiol (Paris); 1996 Oct; 45(8):469-79. PubMed ID: 8952741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel anti-arrhythmic agents for the treatment of atrial fibrillation.
    Wettwer E; Christ T; Dobrev D; Ravens U
    Curr Opin Pharmacol; 2007 Apr; 7(2):214-8. PubMed ID: 17303472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Class III drugs on atrial fibrillation.
    Capucci A; Villani GQ; Aschieri D; Piepoli M
    J Cardiovasc Electrophysiol; 1998 Aug; 9(8 Suppl):S109-20. PubMed ID: 9727685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Relationship between duration of arrhythmia and subsequent preventive effect of disopyramide after cardioversion in patients with symptomatic paroxysmal and persistent atrial fibrillation].
    Komatsu T; Yomogida K; Nakamura S; Suzuki O; Horiuchi D; Kameda K; Tomita H; Abe N; Owada S; Oikawa K; Okumura K
    J Cardiol; 2003 Sep; 42(3):111-7. PubMed ID: 14526660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and clinical significance of transformation of atrial fibrillation to atrial flutter in patients undergoing long-term antiarrhythmic drug treatment.
    Riva S; Tondo C; Carbucicchio C; Galimberti P; Fassini G; Della Bella P
    Europace; 1999 Oct; 1(4):242-7. PubMed ID: 11220561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atrial fibrillation: are there gender differences?
    Michelena HI; Ezekowitz MD
    J Gend Specif Med; 2000; 3(6):44-9. PubMed ID: 11253382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical assessment of antiarrhythmic agents for paroxysmal atrial fibrillation guided by modification of electrophysiologic arrhythmogenicity.
    Cosío FG
    J Cardiovasc Electrophysiol; 2005 Jun; 16(6):677; author reply 677. PubMed ID: 15946374
    [No Abstract]   [Full Text] [Related]  

  • 28. Hybrid therapy of atrial fibrillation.
    Santini M; Pignalberi C; Ricci R; Calò L
    Ital Heart J; 2002 Oct; 3(10):571-8. PubMed ID: 12478814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Further data on amiodarone. Evidence based therapy of cardiac arrhythmias].
    Internist (Berl); 1998 Nov; 39(11 Suppl Evidenzbas):1-4. PubMed ID: 9844841
    [No Abstract]   [Full Text] [Related]  

  • 30. Sotalol reverses remodeled action potential in patients with chronic atrial fibrillation but does not prevent arrhythmia recurrence.
    Osaka T; Yamazaki M; Yokoyama E; Ito A; Kodama I
    J Cardiovasc Electrophysiol; 2004 Aug; 15(8):877-84. PubMed ID: 15333078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent.
    Sablayrolles S; Le Grand B
    Curr Opin Investig Drugs; 2006 Sep; 7(9):842-9. PubMed ID: 17002263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug therapy of patients with arrhythmia].
    Sugimoto T
    Nihon Naika Gakkai Zasshi; 1992 Mar; 81(3):407-11. PubMed ID: 1607805
    [No Abstract]   [Full Text] [Related]  

  • 33. [Drug therapy of atrial fibrillation].
    Gloor HO
    Schweiz Med Wochenschr; 1996 Oct; 126(41):1739-47. PubMed ID: 8966506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of atrial fibrillation post-cavotricuspid isthmus ablation in patients with typical atrial flutter: left-atrial size as an independent predictor of atrial fibrillation recurrence.
    Ellis K; Wazni O; Marrouche N; Martin D; Gillinov M; McCarthy P; Saad EB; Bhargava M; Schweikert R; Saliba W; Bash D; Rossillo A; Erciyes D; Tchou P; Natale A
    J Cardiovasc Electrophysiol; 2007 Aug; 18(8):799-802. PubMed ID: 17593230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Atrial fibrillation successfully converted. A new standard in the prevention of recurrence?].
    Fetsch T
    MMW Fortschr Med; 2001 Dec; 143(51-52):10-2. PubMed ID: 11824159
    [No Abstract]   [Full Text] [Related]  

  • 36. [Restoration and maintenance of sinus rhythm in patients with atrial fibrillation. New pharmacological approaches].
    Runge S; Dietz R; Haverkamp W
    Dtsch Med Wochenschr; 2008 Dec; 133(49):2572-8. PubMed ID: 19039713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A perspective on antiarrhythmic drug therapy.
    Jolobe OM
    Am Heart J; 2006 Aug; 152(2):e17; author reply e19. PubMed ID: 16875893
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of Class I drugs on atrial fibrillation.
    Steinbeck G; Remp T; Hoffmann E
    J Cardiovasc Electrophysiol; 1998 Aug; 9(8 Suppl):S104-8. PubMed ID: 9727684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics.
    Dobrev D; Nattel S
    J Cardiovasc Pharmacol; 2008 Oct; 52(4):293-9. PubMed ID: 18791467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antiarrhythmic therapy--recent aspects of pharmacologic treatment].
    Patten M; Meinertz T
    Dtsch Med Wochenschr; 2005 May; 130(21):1325-9. PubMed ID: 15902621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.